Innovative Clinical Trials

This was a one-off funding call and applications for this are now closed.

Grants will typically range from £4 million to £8 million (maximum), for up to seven years.

This scheme was open to applications for innovative, large-scale clinical trials testing multiple interventions that are adaptable in design (for example, multi-arm, multi-stage trials).

Applications were to focus on the testing and development of at least one of the following:

• Novel treatments or treatment combinations;
• Improvements in treatment sequencing/scheduling;
• More personalised treatment approaches, for instance through use of/development of predictive or prognostic biomarkers.

All applications were to:

• Be inclusive by design and have an inclusive recruitment strategy in place to ensure patients were representative of the disease group/subgroups under investigation.
• Have a clearly defined pathway to impact, aiming to achieve paradigm-shifting changes to current clinical practice or disease management for people living with the least survivable blood cancers.

Studies were to focus on patients with blood cancer who, with current clinical management, have a predicted five-year survival of less than 50% at the point of diagnosis.

To read the full remit, head to page one of the full guidance PDF.

Additional expectations for this grant included specific guidelines around Patient and Public Involvement and an inclusive research strategy.

Please make sure to read the application guidance document and our full terms and conditions to understand all of the requirements for this scheme.

If you have any questions about the scheme, please contact us at [email protected]